August 26, 2025
New AI tool for recognizing skin cancer that should be used in NHS

New AI tool for recognizing skin cancer that should be used in NHS

Adults with suspected skin cancer can initially be rated with a new AI tool after it has been approved for the NHS use.

The National Institute for Health and Care Excellence (Nice) said that the technology approved in the next three years will have the potential to shorten waiting times.

It comes when health experts have published a warning about sunscreen before the bank’s holiday weekend.

Melanoma Focus said a large part of the British is often burned and expose themselves to a higher risk of fatal skin cancer.

The new tool for artificial intelligence (KI) Derm (deep ensemble for the detection of malignancy) works through the analysis of images of moles or skin lesions to determine whether they may be cancer -like.

The tool developed by Skin Analytics can be used by employees in the healthcare system who use a smartphone with a high -quality LENS, which is also referred to as a dermoscopic lens to take pictures of suspicious birthmarks or skin lesions.

The pictures are then uploaded to the online platform from Derm, on which AI analyzes the pictures.

In patients whose birthmarks or lesions are identified as potentially cancer -like, a specialist for dermatologist who is known as dermatologist checks the case and creates a plan for the patient.

People whose birthmarks or lesions are not suspicious are either reassured and advice or can be put on an “non -urgent path”.

Nice said that early evidence indicated that the automated use of the tool “roughly halve the number of transfers on dermatologists in urgent skin cancer”.

It was “approved” in the next three years, while further evidence is collected, said Nicht.

“DERM has shown promising results in its ability to distinguish between cancer -like and non -cancer -like skin lesions, whereby the number of transfers on dermatologists could halve within the urgent skin cancer while maintaining patient safety,” said Dr. Anastasia Chalkidou, Healthtech program director at Nice.

Leave a Reply

Your email address will not be published. Required fields are marked *